Skip to content
2000
Volume 7, Issue 1
  • ISSN: 2212-3962
  • E-ISSN: 1574-8901

Abstract

Stroke is the third leading cause of death and the main cause of permanent disability in western countries. Reperfusion within 3 hours of symptoms-onset is the most beneficial of all therapeutic strategies for acute ischemic stroke. Alteplase has been the first thrombolytic treatment approved by FDA. However, its use is still limited to specific patient subgroups and may be complicated by severe side effects, including massive cerebral hemorrhages. This review is aimed at investigating the current and future treatment strategies in ischemic stroke, including new fibrinolytic drugs, sonothrombolysis, mechanical clot retrievals, and recent patents.

Loading

Article metrics loading...

/content/journals/prc/10.2174/157489012799362412
2012-04-01
2025-09-18
Loading full text...

Full text loading...

/content/journals/prc/10.2174/157489012799362412
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test